Temple University

The Johns Hopkins University

Salim Merali

Carlos A Barrero

Wayne Everett Childers

George C Morton

Steven G Kelsen

Oscar Mauricio Perez Leal

Camilo Moncada

Magid A Abou-Gharbia

Kamel Khalili

Jay F Rappaport

Norman J Haughey

Oscar M Perez-Leal

Carlos A Barrerro

Ned Sacktor

Mario Cesar Rico

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis.

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R-R, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders.

Compositions and methods for treatment of insulin resistance

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R-R, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders. 

The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease ('COPD') but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.

Treatment of chronic obstructive pulmonary disease (COPD)

Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.

Detection of HIV-1-associated neurocognitive disorders

Compositions include nucleic acid sequences encoding the C-terminal fragment of fragment (Seg3) of Nuclear factor-erythroid 2 related factor 2 (Nrf2). These compositions provide a target for identification of novel therapeutics having the ability to modulate the translation of Nrf2. Methods of treating subjects are also provided.

Nuclear factor-erythroid 2 related factor 2 (NRF2) biosensors and modulators of NRF2

Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of diagnosis and/or staging are provided as well. Further provided is a method for treating COPD.

Diagnosis and treatment of chronic obstructive pulmonary disease (COPD) based on elevated levels of extracellular H3 protein

The invention provides an isolated nucleic acid having a sequence encoding a spermidine/spermine acetyltransferase ('SSAT'), wherein translation of an mRNA comprising the encoded SSAT has increased basal translation and increased stimulated translation, compared to a wild-type mRNA encoding SSAT. Methods of use for the nucleic acid are also provided. Methods and compositions are also provided for reducing ischemia-reperfusion injury in organs or tissue for transplantation.

Growing community of inventors

Bryn Mawr, PA, United States of America

Salim Merali